Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More A trio of scientists consisting of Demis Hassabis, co-founder and CEO of ...

The researchers behind the AlphaFold artificial-intelligence (AI) system have won one of this year’s US$3-million Breakthrough prizes — the most lucrative awards in science. Demis Hassabis and John ...

AlphaFold 3 extends beyond protein structures to model DNA, RNA, and all molecular structures vital to life. This advancement promises transformative applications in medicine, agriculture, materials ...

An AI breakthrough from an Alphabet-owned startup is speeding up the hunt for new drugs. The technology, called AlphaFold2, has been used by over 1 million researchers to study proteins. Several ...

AlphaFold arrived as a technical moonshot that suddenly made protein structures feel like software rather than secrets of nature, and five years on it has rewired how laboratories plan experiments, ...

The AI tool AlphaFold has been improved so that it can now predict the shape of very large and complex protein structures. Linköping University researchers have also succeeded in integrating ...

Popularly known as the “Oscars of Science,” the 2023 Breakthrough Prize awardees were announced yesterday. The prize recognizes scientists who have made game-changing discoveries in life sciences, ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more Google DeepMind and Isomorphic Labs today ...

Add Yahoo as a preferred source to see more of our stories on Google. A DeepMind model of a 3D molecular structure from a common cold virus (Google DeepMind) (Google Deepmind) Google’s artificial ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...